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The present study aimed to estimate the prevalence of elderly using potentially inappropriate medications 
(PIM) and with occurrence of potentially hazardous drug interactions (PHDI); to identify the risk 
factors for the prescription of PIM and to evaluate the impact of pharmaceutical intervention (PI) for 
the prescription of safer therapeutic alternatives. Therefore, a cross-sectional study was performed in 
a long-term care facility in São Paulo State, between December/2010 and January/2011. The medical 
records of the patients ≥60 years old who took any drugs were consulted to assess the pharmacotherapeutic 
safety of the medical prescriptions, in order to identify PIM and PHDI, according to the Beers (2003) 
and World Health Organization criteria, respectively. PI consisted of a guidance letter to the physician 
responsible for the institution, with the suggestions of safer equivalent therapeutics. Approximately 
88% of the elderly took at least one drug, and for 30% of them the PIM had been prescribed. Most of 
the PIM identified (53.4%) act on the central nervous system. Among the 13 different DI detected, 6 are 
considered PHDI. Polypharmacy was detected as a risk factor for PIM prescription. After the PI there 
was no change in medical prescriptions of patients who had been prescribed PIM or PHDI. The data 
suggests that PI performed by letter, as the only interventional, method was ineffective. To contribute 
it a wide dissemination of PIM and PHDI among prescriber professionals is necessary for the selection 
of safer treatment for elderly. Additionally, a pharmacist should be part of the health care team in order 
to help promote rational use of medicines.
Uniterms: Drugs/interactions. Elderly people/inappropriated use of medicines. Long-term care facility. 
Medication/errors. Safety management.
O presente estudo teve como objetivos estimar a prevalência de idosos em uso de medicamentos 
potencialmente impróprios (MPI) e com ocorrência de interações medicamentosas potencialmente 
perigosas (IMPP); identificar os fatores de risco para a prescrição de MPI e avaliar o impacto de 
intervenção farmacêutica (IF) para a prescrição de alternativas terapêuticas mais seguras. Para tanto, 
realizou-se estudo transversal em instituição de longa permanência do interior de São Paulo, de 
dezembro/2010 a janeiro/ 2011. Os prontuários médicos dos pacientes ≥60 anos e que utilizavam pelo 
menos um medicamento foram consultados para avaliar a segurança farmacoterapêutica das prescrições 
médicas, identificando-se os MPI e as IMPP, segundo critérios de Beers (2003) e o critério da Organização 
Mundial da Saúde, respectivamente. A IF constou de carta de orientação ao médico da instituição, com 
sugestão de equivalentes terapêuticos mais seguros. Aproximadamente 88% dos idosos haviam utilizado 
pelo menos um medicamento e, para 30% deles, havia pelo menos um MPI prescrito. A maioria dos MPI 
identificados (53,4%) age no sistema nervoso central. Entre as 13 interações medicamentosas detectadas, 
6 são consideradas IMPP. A polimedicação foi detectada como fator de risco para a prescrição de MPI. 
Após a IF, não houve alterações nas prescrições médicas dos pacientes que apresentavam MPI e IMPP 
prescritos. Os dados sugerem que IF realizadas por cartas, como único método interventivo, não são 
efetivas. Para contribuir com a seleção de farmacoterapia mais segura para idosos é necessária ampla 
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divulgação dos MPI e IMPP entre os profissionais prescritores. Além disso, o farmacêutico deve fazer 
parte das equipes de saúde para auxiliar na promoção do uso racional de medicamentos.
Unitermos: Medicamentos/interação. Idosos/uso impróprio de medicamentos. Assistência de longa 
duração. Medicação/erros. Gerenciamento de segurança. 
INTRODUCTION
Brazil is in a demographic transition process, in 
which a marked population aging is observed. It is es-
timated that in 2020 the country will be the sixth in the 
world as regards population of elderly people (Carvalho, 
Garcia, 2003). As a result, an epidemiologic transition is 
also observed, with changes in the morbidity and mortality 
profiles (IBGE, 2009), since the country has passed from 
the typical profile of a young population to one character-
istic of seniors, with more complex diseases and expensive 
treatments (Gordilho et al., 2000) Thus, due to clinical 
conditions of geriatric patients, the use of polypharmacy 
to treat their pathologies is frequent, which favors the oc-
currence of medication errors, such as the prescription of 
potentially inappropriate medication (PIM) and potentially 
hazardous drug interactions (PHDI). 
Medications are considered inappropriate when the 
risk of their use overcomes the benefit (Beers et al., 1991), 
once they are drugs with high risk of leading to adverse 
drug reactions (ADR), without sufficient evidence of 
benefits, and when safer pharmacotherapeutic alternatives 
are available (Gallagher et al., 2008a; Fick et al., 2003). 
Furthermore, the exposure to PIM may increase the utiliza-
tion of health care services (Fick et al., 2008) and medical 
costs (Akazawa et al., 2010).
The aging process induces physiological alterations 
in the body, such as reduction in rates of hepatic clear-
ance, glomerular filtration, muscle mass and homeostasis 
mechanisms (Corsonello et al., 2010). These changes can 
influence pharmacokinetic and pharmacodynamic pa-
rameters. Therefore, it is necessary to elaborate criteria to 
provide safe and rational therapeutic schemes for seniors 
(Klotz et al., 2008). However, the prescription of PIM is 
common among older people (Laroche et al., 2007) and, in 
spite of the recognized gravity of the problem, there is no 
consensus about the best form of prevention (O’Mahony, 
Gallagher, 2008).
Castelino et al. (2009) state that promising results 
are expected with pharmaceutical intervention (PI) regard-
ing the safety assessment of prescriptions for elderly peo-
ple. In these analyses, tools that combine explicit (Bongue 
et al., 2009) and implicit indicators of prescriptions can 
be used to see PIM, being the Beers criteria (Fick et al., 
2003) the most commonly adopted, since it is the most dis-
seminated method in the literature (O’Mahony, Gallagher, 
2008). However, the application of these instruments must 
not substitute clinical and pharmacological analyses for 
the selection of drugs for patients.
In this context, since the proportion of PIM takers 
is an important indicator of medical-sanitary assistance, 
useful to evaluate nursing homes (Rozenfeld, 2003), and 
considering that pharmacoepidemiological studies rarely 
include elderly living in these institutions (Morais, 1998), 
the present study was aimed to: estimate the prevalence 
of institutionalized elderly people using PIM; identify the 
PIM taken and the potentially hazardous drug interactions 
(PHDI); propose a pharmaceutical intervention for physi-
cians, and evaluate its impact on the prescription of safer 
therapeutic alternatives for the elderly.
METHODS
A cross-sectional study was performed in a public 
long-term care facility located in the state of São Paulo, 
Brazil, from December 2010 to January 2011. All data was 
obtained from the medical records of the elderly people 
residing in the institution. Those who were ≥ 60 years old 
and had taken at least one drug were considered eligible 
for the study. The medical records which were illegible or 
lacked information regarding drugs were excluded. 
A validated form was used for data collection. This 
instrument included the identification of the patient (ini-
tials of the name and date of birth), demographic charac-
teristics [gender and age group (I: 60 to 69 years; II: 70 to 
79 years; III: ≥80 years)] and the drugs taken four weeks 
prior to data collection. Beers criteria (Fick et al., 2003) 
were used to identify PIM, since it is the instrument most 
widely used in literature (O’Mahony, Gallagher, 2008), 
and also lists the drugs that should be avoided, indepen-
dently of the diagnosis or clinical condition of the patient.
PIM identified were classified regarding therapeutic 
classes, according to the Anatomical Therapeutic Chemi-
cal Code (ATC code); if they belonged or not to the na-
tional list of essential medicines (RENAME 2010) (based 
on the effectiveness, safety, quality and cost criteria), and 
according to the severity of the outcomes related to the use 
of these drugs (Fick et al., 2003). The drug interactions 
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(DI) were detected through MICROMEDEX® database 
(accessed through the DRUGREAX in www.portaldapes-
quisa.com.br address) and the labels of the drugs approved 
by the National Agency of Sanitary Vigilance (ANVISA). 
DI related to PIM were classified according to the severity 
(major, moderate and minor) and their potential hazard 
(WHO, 2004).
Only one Pharmaceutical intervention (PI) was made 
which comprised the elaboration of a guideline letter to 
the physician responsible for the long-term care facility. 
This document contained the identification of the elderly 
who had taken PIM, the PIM utilized and the DI observed, 
as well as the suggestions of safer pharmacotherapy for 
this age group, which was selected based on the scientific 
literature (pharmacology books and papers published in 
PUBMED database). After PI, medical records of patients 
who had taken PIM and experienced DI were consulted 
to compare the prevalence of PIM prescription before 
and after intervention, and to assess the impact of this 
methodology.
Identified PIM and observed DI were presented 
in absolute and relative frequencies. Odds ratio (OR) of 
gender was calculated to identify risk factor for the use of 
PIM. Chi-square and Mann-Whitney tests were applied 
in order to assess association among age groups and use 
of PIM, as well as statistical differences between patients 
who use polypharmacy from those who do not, respec-
tively. The level of significance was set at 5 %.
The study protocol was approved by the Ethics Com-
mittee in Research of UNIFESP.
RESULTS
During the period of the study, 141 subjects lived in 
the long-term care institution, being that 21 of them did 
not meet the inclusion criteria (five were aged < 60 years 
and 16 did not take any drugs) and 120 (88.2%) were 
considered eligible for the research.
The estimated prevalence of elderly using PIM 
was 29.2% (35/120). Most of them were women [65.7% 
(23/35)], although gender was not detected as risk factor 
for use of PIM [OR=1.27; IC=95% (0.6-2.9); p=0.56].
Regarding age groups, 21 elderly belonged to group 
I, 40 to group II and 59 to group III, of whom 10, 11 and 
14 patients, respectively, had taken PIM. However, there 
was no association among the prescription of PIM and age 
group (p=0.11). Therefore, there is no evidence that the 
older elderly (group III) are more affected by the prescrip-
tion of inappropriate drugs.
According to Mann-Whitney statistical test, PIM 
takers administered more drugs (p<0.0001) than patients 
without use of PIM, indicating that polypharmacy increas-
es the odds of PIM prescription among elderly people.
Out of the 116 different drugs prescribed for the 
elderly, 14 (12.1%) are considered PIM (Table I), out of 
which seven (50.0%) (amiodarone, amitriptyline, diazepam, 
digoxin, fluoxetine, methyldopa and nitrofurantoin) are es-
sential drugs, according to RENAME 2010 and 16th Model 
List of Essential Medicines of World Health Organization 
(2010). Most PIM utilized act on the central nervous system 
(53.4%), followed by 33.3% which act on the cardiovascular 
system (Table I). For 64.3% (9/14) of the PIM identified, the 
use was classified as highly severe hazardous (Fick et al., 
2003) (Table I). Thirteen DI involving PIM were observed 
in 22 prescriptions; six of them (46.1%) being potentially 
hazardous according to the WHO (WHO, 2004) and 15.4% 
(2/13) have major severity (Table II).
In the phase of pharmaceutical intervention, safer 
therapeutic equivalents were suggested for the elderly 
regarding the 14 PIM identified (Table III). 
However, after the guidance letter (PI) was handed 
in to the physician responsible for the institution, there 
was no change in drug prescriptions of the inpatients who 
were taking PIM. Therefore, none of the safer therapeutic 
equivalents suggested were prescribed as a substitute of 
PIM identified.
DISCUSSION
The Beer’s List (Fick et al., 2003) is the most ap-
plied criteria in the literature for assessing the quality of 
medical prescription for the elderly. It comprises two lists 
of medicines, being that the first comprehends 48 drugs or 
classes of drugs which should be avoided, independently 
of clinical conditions of the elderly patient; and the second 
one comprises the drugs that should be avoided consider-
ing 20 pathologies or health conditions of the patient. 
According to this list, the prevalence of elderly 
using PIM in the present study was approximately 30%. 
Other researches show that the prevalence of institutional-
ized older people who take at least one PIM ranges from 
27.6% to 46.2% (Ruggiero et al., 2010; Castellar et al., 
2007; Azoulay et al., 2005). The prescription of PIM must 
follow judicious protocols, since their administration 
may double the odds of hospitalization of elderly people 
(Albert et al., 2010), as well as the demand for health 
services (Fick et al, 2008). It can also generate hospital 
expenses (Akazawa et al., 2010). Thus, it is necessary that 
health institutions promote continuing education for their 
professionals, in order to allow them to carry-out quality 
medical assistance, considering the elderly needs. Most of 
identified PIM (53.4%) act on the central nervous system, 
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and are considered psychoactive drugs [benzodiazepines 
(28.9%), antidepressants (15.6%) and neuroleptics 
(8.9%)]. Lucchetti et al. (2010) observed that 58.9% of 
the older people living in a long-term care facility were 
prescribed psychotropic drugs, mainly antidepressants 
and neuroleptics drugs. The prevalence of psychoactive 
substances reported in both studies may be explained by 
several factors, including: the pattern of utilization of these 
substances (chronic and continuous use by major adults 
and elderly people) (Laranjeira, Castro, 1999; Fraser, 
1998), the high incidence of psychiatric diseases among 
institutionalized patients (Nakayama et al., 2004), and 
drug dependence or abuse. 
The phenomenon of drug dependence in elderly 
people may be associated with misuse and abuse of 
psychotropic drugs, because according to Orlandi et al. 
(2005), many older patients start taking these substances 
when they are young or young adults. However, to prevent 
and minimize the negative outcomes associated with ir-
rational and incorrect use, the treatment should not exceed 
four weeks, according to the World Health Organization 
(WHO, 1983).
Drug advertisements contribute to inappropriate 
prescriptions of psychoactive drugs as well. These kinds 
of publications have low level of scientific evidence and 
lack of reliability and accuracy of information disclosed 
to doctors (Mastroianni et al., 2008). The absence of ad-
equate public policies in order to regulate information on 
drugs which is disseminated to physicians and the lack of 
monitoring of the content of advertisement (Mastroianni 
et al., 2003) are also factors that allow prescription er-
rors. Thus, prescribers should have a critical attitude of 
regarding the drugs advertisements from pharmaceutical 
companies (Mastroianni et al., 2008), and should also 
properly assess the risk/benefit ratio of drug usage, based 
on officially recognized scientific literature. Greater atten-
tion should be given to patients considered at risk, such as 
the elderly people.
TABLE I - Frequency of the potentially inappropriate medication identified according to Beers criteria (Fick et al., 2003), classified 
according to the ATC, the severity of its use and the justification for being considered inappropriate for the elderly. Araraquara, 
SP, Brazil (n=14)
ATC code Drug N Severity Justification for inappropriate use
Nervous System
diazepam 13 (28,9) High Long half-life in elderly patients; causes prolonged sedation, increasing risks of falls and fractures.
amitriptyline 4 (8,9) High Causes severe anticholinergic effects. 
thioridazine 4 (8,9) High Great potential for causing extra-pyramidal adverse effects and adverse effects in the central nervous system.
fluoxetine 3 (6,7) High
Long half-life and risk of producing excessive stimulation in the 
central nervous system, sleep problems and increase in agitation; 
safer alternatives are available.
Cardiovascular
clonidine 1 (2,2) Low Potential orthostatic hypotension and adverse effects on the central nervous system.
methyldopa 5 (11,2) High Can cause bradycardia and exacerbate depression in elderly.
digoxin 3 (6,7) Low
Must not exceed 0.125mg/d, except in treatment of atrial 
arrhythmias; reduces the renal clearance and can lead to renal toxic 
effects. 
codergocrine 2 (4,4) Low Has not proved effective in the doses used.
amiodarone 2 (4,4) High It is associated with problems in the QT interval and risk of causing 
torsades de pointes; lack of efficacy in elderly.
doxazosin 1 (2,2) Low Potential hypotension, dry mouth and urinary problems.
hydroxyzine 1 (2,2) High Has potent anticholinergic activity.
Antibiotic nitrofurantoin 3 (6,7) High Potential renal problems; safer alternatives are available.
Genito-urinary oxybutynin 2 (4,4) High
Is not well tolerated by elderly for causing anticholinergic adverse 
effects, sedation and weakness; furthermore, its effectiveness in 
doses tolerated by the elderly is questionable.
Digestive cimetidine 1 (2,2) Low Adverse effects on the central nervous system, including confusion.
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TABLE II - Frequency of the drug interactions detected, involving PIM, according to the severity, those considered potentially 
hazardous and the negative clinical outcomes for the elderly, Araraquara, SP, Brazil (n=13)
Dug-drug interaction
N Result Potentially hazardous SeverityDrug A Drug B
amitriptyline diazepam 1 (4.5) May cause psychomotor deficit No Moderate
amitriptyline phenytoin 1 (4.5) Can result in toxic effect of phenytoin Yes Moderate
amitriptyline carbamazepine 1 (4.5) Can decrease effectiveness of amitriptyline Yes Moderate
amitriptyline haloperidol 1 (4.5) Can raise the risk of cardiotoxicity Yes Major
diazepam haloperidol 4 (18.2) Can raise the sedative effect No -*
diazepam phenytoin 3 (13.7) May change the serum concentration of 
phenytoin
No Moderate
diazepam hydrochlorothiazide 3 (13.7) Can raise the hypotensive effect No -*
diazepam methyldopa 2 (9.2) Can raise the hypotensive effect No -*
digoxin furosemide 1 (4.5) Can result in digitalis toxicity Yes Moderate
digoxin hydrochlorothiazide 1 (4.5) Can result in digitalis toxicity Yes Major
digoxin nifedipine 1 (4.5) Can result in digitalis toxicity Yes Moderate
methyldopa clonazepam 1 (4.5) Can raise the hypotensive effect No -*
methyldopa hydrochlorothiazide 2 (9.2) Can raise the hypotensive effect No -*
TOTAL 22
*- Micromedex database does not detect the concomitant use of these drugs as drug interaction. Therefore, it was not possible to 
analyze the severity. However, in the WHO Model Formulary (2004) there are descriptions of these drug interactions.
Studies have shown that polypharmacy is a risk fac-
tor for PIM prescription (Varallo et al., 2011; Ruggiero 
et al., 2010; Locatelli et al., 2010; Azoulay et al., 2005). 
Our findings corroborate data of the literature, since older 
people who used five or more medications had higher 
number of prescribed PIM when compared with elderly 
individuals who are not polypharmacy users (p<0.0001). 
However, for geriatric patients aged ≥ 80 years, there is 
no evidence that polypharmacy increases the odds of PIM 
prescription. According to Azoulay et al. (2005), possible 
reasons for the occurrence of this prescription error are 
related to the absence of safer equivalent therapeutics 
available for use in the elderly people, the inexperience of 
physicians in clinical practice and the need for adjustments 
in the curriculums of health courses. 
Castelar et al. (2007) found that polypharmacy is 
also a risk factor for the occurrence of serious and poten-
tially hazardous drug interactions (PHDI). In the present 
study, 22 drug interactions involving PIM were identified, 
of which 27.3% (6/22) are considered PHDI, according 
to WHO criteria (WHO, 2004). Considering that the 
elderly people are more predisposed to the occurrence of 
drug interactions due to polypharmacy, the prescriber has 
the responsibility to elaborate therapeutic schemes with 
fewer numbers of drugs and to consider the possibility 
of non-pharmacological treatments, in order to avoid co-
prescription with the potential to interact with each other. 
On the other hand, if the prescription of drug interaction 
is inevitable (when there are no other options available), 
it is necessary to adjust the dose or the time of administra-
tion of each drug, to minimize or prevent adverse clinical 
outcomes that might occur due to the drug interaction 
(WHO, 2004; Seymour, Routledge, 1998).
The proposed methodology of pharmaceutical 
intervention (PI) did not bring about changes in drug 
prescriptions for elderly people who had prescribed PIM 
and identified PHDI. Although the PI did not reach the 
expected impact, it is relevant to highlight that it may 
contribute to improve the quality of medical prescrip-
tion for elderly people, once most of the physicians lack 
knowledge regarding explicitly validated criteria for safe 
drug use in the elderly, such as Beers criteria (Beers, 1991; 
Beers et al., 1997; Fick at al., 2003) and Screening Tool 
of Older Person’s Prescriptions – STOPP – (Gallagher et 
al., 2008b; Gallagher et al., 2009). Since the list of medi-
cines approved by sanitary surveillance may vary among 
countries, it is also important that each country develop 
a proper consensus in order to establish a list of PIM, as 
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observed in the study conducted by Holt et al. (2010).
One of the reasons which may explain the poor 
results obtained is that the letter may not be the most ef-
fective method to lead to changes in the parameters evalu-
ated, possibly due to the distance and impersonality among 
the professionals involved (physicians and pharmacists). 
Grimshaw et al. (2001) found that simple interventions, 
such as sending educational materials for physicians, 
are generally ineffective in promoting changes in the 
behavior of those professionals, when used as the only 
interventional method. However, the authors suggest that 
this practice is useful to raise awareness of the problem. 
They also noted that multifaceted interventions should be 
used based on the factors involved in the resistance health 
professionals have as regards changing their prescription 
behavior. This fact can be explained by the principle of 
andragogy, which asserts that adult apprenticeship is much 
more effective when it is related to factors of information 
acquisition (either through visual or listening sources), 
associated with practical applications of concepts and 
particular experiences. Therefore, educational intervention 
with other techniques, in addition to the expository meth-
TABLE III - Pharmaceutical intervention: suggestion of therapeutic equivalents possibly safer for the elderly, and the justification 
of the choice. Araraquara, SP, Brazil (n = 14)
Drug Therapeutic 
Equivalent 
Justification
Amiodarone propranolol propranolol has reduced presystemic metabolism, has no active metabolites, and presents 
cardioprotective effects (Hardman, Limbird, 2003). 
Amitriptylin sertraline sertraline has fewer anticholinergic effects, sedation, hypotension and cardiac effects 
(Hardman, Limbird, 2003).
Cimetidine omeprazole omeprazole is well tolerated even at high doses and does not cause CNS side effects 
(Silva., 2006).
Clonidin losartan It is suggested as a substitution for other antihypertensive drug, such as losartan, except 
calcium channel blockers and reserpine (Laroche et al., 2007). 
Diazepam short acting 
benzodiazepine
Short acting benzodiazepines are recommended , such as lorazepam or oxazepam, 
since they do not have active metabolites and are metabolized only in conjunction with 
glucuronic acid (Hardman, Limbird., 2003). 
Digoxin - Requires doses lower than 0.125 mg/day or maintains the serum concentrations of the 
drug between 0.5 and 1.2 ng/ml (Fick et al., 2003).
Doxazosin losartan The use of doxazosin is indicated only if there is contraindication to other antihypertensive 
drugs or if the patient has severe hypertension, starting with low doses and slow adjustment 
to the lowest effective dose. Otherwise, substitute the drug to other class in accordance 
with other possible comorbidities (Cavalcanti et al., 2006).
Fluoxetine sertraline sertraline has fewer anticholinergic effects, sedation, hypotension and cardiac effects 
(Hardman, Limbird, 2003).
Hydroxyzine loratadine It is preferable to the use of loratadine due to its reduced sedation (Laroche et al., 2007). 
Codergocrine ginkgo biloba Ginkgo biloba is effective and causes no significant adverse effects (Kleijnen, Knipschild, 
1992).
Methyldopa losartan It is suggested as a substitution for other antihypertensive drugs, such as losartan, except 
calcium channel blockers and reserpine (Laroche et al., 2007). 
Nitrofurantoin ciprofloxacin ciprofloxacin is well tolerated, it also has broad spectrum and is indicated for urinary tract 
infections (Korolkovas, França, 2009; Hardman, Limbird, 2003).
oxybutynin tolterodine tolterodine causes few cognitive adverse effects and has greater selectivity for bladder 
(Hardman, Limbird, 2003)
Tioridazine fluphenazine fluphenazine has weaker sedative, anticholinergic and hypotensive effects (Korolkovas, 
França, 2009).
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od, including all experts who assist the elderly residents in 
the studied institution, would be an important component 
to promote effective pharmacotherapeutic adjustments for 
patients who had PIM or DI prescribed. 
Another issue that contributed to the non-adherence 
to the intervention may be the drugs selected in the long-
term care, which are arising from Public Health Sector. 
In the institution studied, the selection of drugs is based 
on the national and municipal lists of essential medicines. 
Therefore, half of the safer alternatives proposed are not 
available (e.g. short-acting benzodiazepines, fluphenazine, 
Ginkgo biloba, sertraline and tolterodine), since they are 
not considered essential medicines, according to the Na-
tional List of Essential Medicines (RENAME 2010) and 
the Municipal List of Essential Medicines (REMUME). 
Moreover, the residents of the institution did not have fi-
nancial means that would allow the purchase of these safer 
therapeutic alternatives. Thus, the inclusion of the thera-
peutic equivalents proposed in the Brazilian public health 
drug lists (RENAME and REMUME) is recommended, 
especially fluphenazine and lorazepam (short-acting ben-
zodiazepinic) which are contemplated in the 16th WHO 
Model List of Essential Medicines, in order to contribute 
to the indication of safer drugs for the elderly people.
Strategies that may be useful to prevent the use of 
PIM and the prescription of PHDI are the wide dissemina-
tion, among health professionals, of lists of medications 
considered inappropriate for the elderly and the drugs 
involved in DI. Grimshaw et al. (2001) conducted a sys-
tematic review of studies of educational interventions and 
found that the disclosure and use of educational reminders 
are effective strategies that can be employed to change 
the behavior of health professionals. In addition, the 
pharmaceutical care for elderly people should be an active 
practice in all levels of health care, in order to detect and 
solve real and/or potential drug related problems, and to 
prevent negative outcomes associated with medications, 
as well as to ensure drugs and patient safety.
Study limitations
The main limitation of the present study is the 
sample size, which makes it difficult to infer data for other 
long-term care institutions. Moreover, we did not have 
access to the physicians who were not linked to the institu-
tion studied. Therefore, the intervention was performed for 
a single prescribing professional, who was responsible for 
the pharmacotherapy management in the institution and 
who did not adhere to the suggestions proposed. Thus, if 
all prescribers involved in the treatment of the elderly had 
been identified and included in pharmaceutical interven-
tion, maybe alterations in the prescriptions which con-
tained PIM could have been observed. Furthermore, the 
prevalence of use of PIM may have been underestimated, 
due to Beers criteria, since this method does not cover all 
drugs available in Brazil and includes several drugs that 
have not been approved for use in our country.
CONCLUSION
PIM prescription is common for elderly residents in 
long-term care facilities. Therefore, the analysis of drug 
prescription is recommended, especially for older patients 
receiving polypharmacy and for those who use psychoactive 
drugs, in order to prevent drug dependence; deal with the 
cases in which there is abuse of drugs, or when judicious 
pharmacotherapeutic management for withdrawal and/or 
replacement of drugs is required. Therefore, it is possible 
to detect and prevent drug related problems and negative 
outcomes associated with medications, to propose changes 
in treatment regimens with the objective of preventing seri-
ous and hazardous drug interactions and to detect the need 
of inclusion of safer therapeutic equivalents for the elderly 
(such as short-acting benzodiazepines, fluphenazine, the 
Ginkgo biloba, sertraline and tolterodine) in the national 
and municipal lists of essential medicines.
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